| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Alpo Vuorio | Q92139180 |
| Petri T Kovanen | Q60985020 | ||
| P2093 | author name string | Matti J Tikkanen | |
| P2860 | cites work | Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia | Q24294711 |
| Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society | Q27024882 | ||
| Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein | Q28186061 | ||
| Mutations in PCSK9 cause autosomal dominant hypercholesterolemia | Q28202519 | ||
| Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia | Q28262033 | ||
| Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia | Q28282776 | ||
| Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly | Q28624200 | ||
| Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment | Q30485634 | ||
| Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia | Q33386394 | ||
| The role of the microsomal triglygeride transfer protein in abetalipoproteinemia | Q33913539 | ||
| Regulation of plasma cholesterol by lipoprotein receptors | Q34252363 | ||
| Heart-liver transplantation in a patient with familial hypercholesterolaemia | Q34291627 | ||
| Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding | Q34350695 | ||
| Microsomal triglyceride transfer protein (MTP) inhibitors: discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms. | Q34798926 | ||
| Efficacy criteria and cholesterol targets for LDL apheresis. | Q34991553 | ||
| Hypercholesterolemic valvulopathy: an aspect of malignant atherosclerosis | Q35187630 | ||
| Deficiency of low density lipoprotein receptors in liver and adrenal gland of the WHHL rabbit, an animal model of familial hypercholesterolemia | Q35346270 | ||
| Two common low density lipoprotein receptor gene mutations cause familial hypercholesterolemia in Afrikaners | Q35814601 | ||
| Current management of severe homozygous hypercholesterolaemias | Q35830954 | ||
| Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study | Q36104706 | ||
| An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells | Q37278800 | ||
| Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia | Q37304815 | ||
| Preemptive liver transplantation in a child with familial hypercholesterolemia | Q37789441 | ||
| Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment | Q37991466 | ||
| The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels | Q74348259 | ||
| An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits | Q77449866 | ||
| Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia | Q81159437 | ||
| Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan | Q82829490 | ||
| Liver transplantation as treatment for familial homozygous hypercholesterolemia: too early or too late | Q83159484 | ||
| Liver transplantation as a treatment option for three siblings with homozygous familial hypercholesterolemia | Q83207278 | ||
| Guidelines for the management of familial hypercholesterolemia | Q85263939 | ||
| Efficacy of mevinolin as adjuvant therapy for refractory familial hypercholesterolaemia | Q93549271 | ||
| The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease | Q38077331 | ||
| Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia | Q38086580 | ||
| Microsomal transfer protein inhibition in humans | Q38099720 | ||
| Recent advances in the treatment of homozygous familial hypercholesterolaemia | Q38120461 | ||
| Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. | Q38122663 | ||
| Prenatal diagnosis of homozygous familial hypercholesterolaemia. Expression of a genetic receptor disease in utero | Q39480663 | ||
| Familial hypobeta-lipoproteinemia: studies in 13 kindreds | Q40142851 | ||
| Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe | Q42272692 | ||
| Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia | Q42545652 | ||
| Analysis of LDL receptor gene mutations in Italian patients with homozygous familial hypercholesterolemia | Q42692028 | ||
| Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial | Q43130496 | ||
| Liver transplantation for homozygous familial hypercholesterolemia: two case reports. | Q43274476 | ||
| Emerging low-density lipoprotein therapies: Microsomal triglyceride transfer protein inhibitors | Q43584659 | ||
| MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion | Q43804978 | ||
| Diaminoindanes as microsomal triglyceride transfer protein inhibitors | Q43821275 | ||
| Homozygous familial hypercholesterolemia in Lebanon: a genotype/phenotype correlation | Q43959430 | ||
| Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. | Q45032463 | ||
| Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia | Q45831677 | ||
| Lomitapide for homozygous familial hypercholesterolaemia | Q46303775 | ||
| Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy | Q46408437 | ||
| Long-term effects of LDL apheresis in patients with severe hypercholesterolemia | Q46478476 | ||
| Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia | Q46573174 | ||
| A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia | Q46603544 | ||
| Non-invasive detection of aortic and coronary atherosclerosis in homozygous familial hypercholesterolemia by 64 slice multi-detector row computed tomography angiography | Q46990100 | ||
| Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia | Q48410692 | ||
| A host of hypercholesterolaemic homozygotes in South Africa. | Q53958221 | ||
| Sudden Death in a 4-Year-Old Boy: A Near-Complete Occlusion of the Coronary Artery Caused by an Aggressive Low-Density Lipoprotein Receptor Mutation (W556R) in Homozygous Familial Hypercholesterolemia | Q59436465 | ||
| Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: Lack of effect on low-density lipoprotein concentrations or turnover | Q68452596 | ||
| Natural history and cardiac manifestations of homozygous familial hypercholesterolaemia | Q68567438 | ||
| Homozygous familial hypercholesterolemia among French Canadians in Québec Province | Q69960600 | ||
| The Lebanese allele at the low density lipoprotein receptor locus. Nonsense mutation produces truncated receptor that is retained in endoplasmic reticulum | Q70157766 | ||
| In vivo metabolism of apolipoproteins A-I and E in patients with abetalipoproteinemia: implications for the roles of apolipoproteins B and E in HDL metabolism | Q72537480 | ||
| Lipoprotein(a) in homozygous familial hypercholesterolemia | Q73435180 | ||
| Decreased secretion of ApoB follows inhibition of ApoB-MTP binding by a novel antagonist | Q73685317 | ||
| Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia | Q73901930 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | human digestive system | Q9649 |
| triglyceride | Q186319 | ||
| heterocyclic compound | Q193430 | ||
| membrane protein | Q423042 | ||
| hypercholesterolemia | Q762713 | ||
| mechanism of action | Q3271540 | ||
| transport protein | Q2111029 | ||
| cell surface receptor | Q2476074 | ||
| familial hypercholesterolemia | Q2711291 | ||
| homozygous familial hypercholesterolemia | Q15815863 | ||
| homozygosity | Q114049690 | ||
| anticholesteremic agents | Q50429847 | ||
| dyslipidemia | Q66291209 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 263-270 | |
| P577 | publication date | 2014-05-06 | |
| P1433 | published in | Vascular Health and Risk Management | Q7916443 |
| P1476 | title | Inhibition of hepatic microsomal triglyceride transfer protein - a novel therapeutic option for treatment of homozygous familial hypercholesterolemia | |
| P478 | volume | 10 |
| Q98224918 | Analysis of Differentially Expressed Genes and Molecular Pathways in Familial Hypercholesterolemia Involved in Atherosclerosis: A Systematic and Bioinformatics Approach |
| Q38366873 | Chylomicronaemia--current diagnosis and future therapies |
| Q92219039 | Current Treatment of Familial Hypercholesterolaemia |
| Q91972518 | Familial hypercholesterolemia with early coronary atherosclerotic heart disease: A case report |
| Q58561315 | Lipid management in patients with chronic kidney disease |
| Q38269605 | Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances |
| Q47442599 | Tendon Pathology in Hypercholesterolemia and Familial Hypercholesterolemia |
Search more.